Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

The Mumbai-based firm expects a quick recovery in FY27, and is on track to achieve its target of becoming a $2-billion ...

Qiagen has a relatively well-diversified portfolio across four segments. Find out my recommendation on QGEN stock here.

Last week, it was announced that Genentech, a founding company in the biotech industry, plans to build a $700 million, ...